Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise
beta
Latest Financials
Filings:
By Category
By Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
Company Exhibits:
Indentures
Material Contracts & Credit Agreements
Plans of Reorganization
Articles and Bylaws
Underwriting Agreements
SEC Edgar
Aditxt, Inc.
SIC 2834 · Pharmaceutical Preparations
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Aditxt, Inc.
SIC 2834 · Pharmaceutical Preparations
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Aditxt, Inc.
SIC 2834 · Pharmaceutical Preparations
Support
about
terms
$
ADTX
Aditxt, Inc.
CIK:
0001726711
|
SEC Filings
Cash Flow
v3.26.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
$ (16,189,200)
$ (5,952,465)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation from asset purchase
10,000
Depreciation expense
47,882
68,450
Amortization of intangible assets
834
833
Amortization of debt discount - note payable
24,687
200,284
Change in fair value of derivative liability
11,800,798
(13,145)
Change in fair value of Evofem warrants
(25,004)
Impairment of fixed assets
32,275
Changes in operating assets and liabilities:
Accounts receivable
(11,974)
1,317
Prepaid expenses
294,310
(59,237)
Deposits
(92,174)
Inventory
9,289
2,188
Accounts payable and accrued expenses
(562,609)
(5,879,446)
Net cash used in operating activities
(4,578,712)
(11,713,395)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of fixed assets
(10,379)
Net cash used in investing activities
(10,379)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes and convertible notes payable, net of offering costs
2,855,000
Repayments of note payable, related party
(115,000)
Repayments of note payable
(1,428,921)
(2,778,978)
Common stock, preferred stock, and warrants issued for cash, net of issuance costs
603,261
20,169,072
Cash from subscription receivable
1,108,751
Redemptions of A-1 preferred stock
(369,996)
Redemptions of C-1 preferred stock
(7,027,065)
Net cash provided by financing activities
1,659,344
11,356,780
NET DECREASE IN CASH
(2,929,747)
(356,615)
CASH AT BEGINNING OF PERIOD
3,198,599
833,031
CASH AT END OF PERIOD
268,852
476,416
Supplemental cash flow information:
Cash paid for income taxes
Cash paid for interest
152,965
1,264,504
NONCASH INVESTING AND FINANCING ACTIVITIES:
Derivative liability from conversion feature on warrants
13,736,777
Derivative liability from conversion feature on preferred stock
9,913,157
ELOC payable
630,105
Series C-1 redemption payable
1,247,367
ELOC commitment fee stock payable
2,250,000
Reclassification of series A-1 preferred shares to liabilities
369,996
Conversion of Series A-1 to common stock
$ 20,000,000